DKA FINANS ApS: Financial statements 2022
CVR: 26028906
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
DKA FINANS ApS (CVR 26028906) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -1 and a net result of DKK -122,475 compared with DKK 6,196,943 the year before. Equity in the 2022 report amounted to DKK -3,794,798.
- Gross Profit
- DKK -1
- Profit/Loss
- DKK -122,475
- Equity
- DKK -3,794,798
- Total Assets
- DKK 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -1 | -122 t. | -3.8 mio. | - |
| 2021 | - | - | 6.2 mio. | -3.7 mio. | - |
| 2020 | - | - | -297 t. | -9.9 mio. | - |
| 2019 | - | - | -293 t. | -9.6 mio. | - |
| 2018 | - | 0 | -283 t. | -9.3 mio. | - |
Official annual report
Keep an eye on DKA FINANS ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
DKA FINANS ApS has published its annual report for 2021. The net result was DKK 6,196,943.
About DKA FINANS ApS
DKA FINANS ApS was a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2001. The company has been dissolved on 25 September 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named DKA PHARMA ApS and IMMUNOLEX THERAPEUTICS ApS. The company has 2 employees (2003). In 2024, the company reported a net result of DKK -140,083 compared with DKK -148,558 the year before. Equity in the 2024 report amounted to DKK -4,083,439.